Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatranPaul A. Reilly, Charles V. Pollack, Robert Dubiel et al.|Thrombosis and Haemostasis|2015Cited by 154